CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation

FRA:AFX • DE0005313704

Current stock price

27.73 EUR
-0.11 (-0.4%)
Last:

This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. AFX.DE Profitability Analysis

1.1 Basic Checks

  • In the past year AFX was profitable.
  • AFX had a positive operating cash flow in the past year.
  • AFX had positive earnings in each of the past 5 years.
  • In the past 5 years AFX always reported a positive cash flow from operatings.
AFX.DE Yearly Net Income VS EBIT VS OCF VS FCFAFX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • The Return On Assets of AFX (4.15%) is better than 62.30% of its industry peers.
  • The Return On Equity of AFX (6.67%) is comparable to the rest of the industry.
  • AFX has a Return On Invested Capital of 5.79%. This is comparable to the rest of the industry: AFX outperforms 52.46% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AFX is below the industry average of 10.31%.
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROIC 5.79%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
AFX.DE Yearly ROA, ROE, ROICAFX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10

1.3 Margins

  • The Profit Margin of AFX (6.34%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of AFX has declined.
  • The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
  • AFX's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 52.76%, AFX is doing worse than 62.30% of the companies in the same industry.
  • AFX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
AFX.DE Yearly Profit, Operating, Gross MarginsAFX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

6

2. AFX.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
  • AFX has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AFX has been reduced compared to 5 years ago.
  • AFX has a better debt/assets ratio than last year.
AFX.DE Yearly Shares OutstandingAFX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AFX.DE Yearly Total Debt VS Total AssetsAFX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • AFX has an Altman-Z score of 2.94. This is not the best score and indicates that AFX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AFX has a Altman-Z score (2.94) which is comparable to the rest of the industry.
  • AFX has a debt to FCF ratio of 4.41. This is a neutral value as AFX would need 4.41 years to pay back of all of its debts.
  • AFX has a Debt to FCF ratio (4.41) which is comparable to the rest of the industry.
  • AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • AFX's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. AFX outperforms 55.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Altman-Z 2.94
ROIC/WACC0.86
WACC6.72%
AFX.DE Yearly LT Debt VS Equity VS FCFAFX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
  • AFX's Current ratio of 2.35 is fine compared to the rest of the industry. AFX outperforms 62.30% of its industry peers.
  • A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
  • The Quick ratio of AFX (1.44) is better than 63.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.44
AFX.DE Yearly Current Assets VS Current LiabilitesAFX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. AFX.DE Growth Analysis

3.1 Past

  • AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.51%.
  • AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
  • The Revenue has been growing slightly by 5.89% in the past year.
  • The Revenue has been growing by 10.78% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.94% on average over the next years. This is quite good.
  • AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.17% yearly.
EPS Next Y-11.59%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
EPS Next 5Y14.94%
Revenue Next Year0.72%
Revenue Next 2Y3.1%
Revenue Next 3Y4.03%
Revenue Next 5Y5.17%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AFX.DE Yearly Revenue VS EstimatesAFX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
AFX.DE Yearly EPS VS EstimatesAFX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

5

4. AFX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • AFX is valuated rather expensively with a Price/Earnings ratio of 18.99.
  • Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 77.05% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of AFX to the average of the S&P500 Index (27.89), we can say AFX is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 14.81 indicates a correct valuation of AFX.
  • AFX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 75.41% of the companies in the same industry.
  • AFX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.50.
Industry RankSector Rank
PE 18.99
Fwd PE 14.81
AFX.DE Price Earnings VS Forward Price EarningsAFX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • AFX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AFX is cheaper than 86.89% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than 78.69% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.61
EV/EBITDA 8.58
AFX.DE Per share dataAFX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)5.79
EPS Next 2Y7.85%
EPS Next 3Y11.93%

4

5. AFX.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.98%, AFX has a reasonable but not impressive dividend return.
  • In the last 3 months the price of AFX has falen by -29.41%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.26, AFX pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, AFX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.98%

5.2 History

  • The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
AFX.DE Yearly Dividends per shareAFX.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
AFX.DE Yearly Income VS Free CF VS DividendAFX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M
AFX.DE Dividend Payout.AFX.DE Dividend Payout, showing the Payout Ratio.AFX.DE Dividend Payout.PayoutRetained Earnings

AFX.DE Fundamentals: All Metrics, Ratios and Statistics

CARL ZEISS MEDITEC AG - BR

FRA:AFX (4/20/2026, 3:31:41 PM)

27.73

-0.11 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-12
Inst Owners23.27%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.48B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.09
Price Target34.74 (25.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.98%
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)-30.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.35%
EPS NY rev (1m)-12.68%
EPS NY rev (3m)-28.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-3.37%
Valuation
Industry RankSector Rank
PE 18.99
Fwd PE 14.81
P/S 1.11
P/FCF 18.61
P/OCF 11.82
P/B 1.17
P/tB 5.13
EV/EBITDA 8.58
EPS(TTM)1.46
EY5.27%
EPS(NY)1.87
Fwd EY6.75%
FCF(TTM)1.49
FCFY5.37%
OCF(TTM)2.35
OCFY8.46%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)N/A
PEG (5Y)5.79
Graham Number27.8812 (0.55%)
Profitability
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROCE 7.81%
ROIC 5.79%
ROICexc 5.89%
ROICexgc 14.08%
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
FCFM 5.98%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Debt/EBITDA 1.61
Cap/Depr 60.61%
Cap/Sales 3.44%
Interest Coverage 10.38
Cash Conversion 60%
Profit Quality 94.37%
Current Ratio 2.35
Quick Ratio 1.44
Altman-Z 2.94
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y-11.59%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
EPS Next 5Y14.94%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year0.72%
Revenue Next 2Y3.1%
Revenue Next 3Y4.03%
Revenue Next 5Y5.17%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year39.7%
EBIT Next 3Y21.85%
EBIT Next 5Y16.25%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%

CARL ZEISS MEDITEC AG - BR / AFX.DE Fundamental Analysis FAQ

What is the fundamental rating for AFX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.


What is the valuation status for AFX stock?

ChartMill assigns a valuation rating of 5 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.


What is the profitability of AFX stock?

CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.


What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.


Can you provide the dividend sustainability for AFX stock?

The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.